Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Scienture Holdings, Inc. Common Stock

SCNX

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.71 – $3.10
Volume 6,018
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.91M
Price / earnings
—
Price / book
0.08×
Price / sales
4.96×
EV / sales
6.36×
EV / EBITDA
-0.81×

Profitability

Earnings per share
-$5.99
Return on assets
-11.21%
Return on equity
-15.34%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.15×
Current ratio
3.04×
Quick ratio
2.97×
Cash ratio
2.71×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.44M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SCNX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$343.64K$56.33K—$590.05K$0$10.26K$53.08K$64.86K
Cost of revenue$7.86K$2.48K$0$15.43K$0$9.59K$50.26K$60.98K
Gross profit$335.78K$53.85K—$574.62K$0$673$2.83K$3.88K
Selling, general and administrative$1.74M$2.43M—$3.74M$3.91M$2.46M$2.44M$1.47M
Research and development$1.17M$809.75K—$179.1K$864.96K$636.3K$1.1M$1.41M
Total operating expenses$3.04M$3.56M—$4.94M$5.16M$3.57M$4.22M$3.5M
Operating income-$2.7M-$3.51M—-$4.36M-$5.16M-$3.57M-$4.21M-$3.5M
Interest expense-$269.79K-$37.02K—-$1.8M-$653.49K-$670.78K-$1.01M-$217.43K
Income before taxes-$2.82M-$3.4M—-$3.61M-$6.72M-$3.06M-$7.34M-$3.18M
Income taxes$0$0—$0$0$0-$534.4K$0
Net income-$2.82M-$3.4M—-$3.61M-$6.72M-$3.06M-$7.16M-$3.18M
Net income attributable to common shareholders-$2.82M-$3.4M—-$3.61M-$6.72M-$3.06M-$7.16M-$3.18M
EBITDA-$2.13M-$2.73M$454.35K-$3.34M-$4.78M-$3.1M-$3.54M-$2.88M
Basic earnings per share-$1.75-$2.00—-$4.75-$12.00-$8.25-$20.62-$33.50
Diluted earnings per share-$1.75-$2.00—-$4.75-$12.00-$8.25-$18.72-$33.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 5, 20261-for-25reverse split